

World's First Proton Therapy Specific Cone Beam CT (CBCT) Solution Goes Clinical

Cancer patients at Penn Medicine now benefit from the most advanced Imaging Guided Proton Therapy (IGPT)

Philadelphia, United States, September 15, 2014 – IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, and Université Catholique de Louvain announced today that the first patient treatment with IBA's Proton Therapy Specific Cone Beam CT (CBCT) was successfully completed at Penn Medicine's Roberts Proton Therapy Center.

As a component of IBA's Image Guided Proton Therapy (IGPT) solution, CBCT provides 3D imaging for increased accuracy in patient treatment. It is fully integrated with IBA's imaging platform *adaPTinsight**, developed in partnership with the Université catholique de Louvain (UCL), to offer fast 6D corrections of patient positioning for IBA's Proteus®PLUS** and Proteus®ONE*** proton therapy solutions.

Dr. James M. Metz, MD, Professor and Vice Chair, Radiation Oncology, Penn Medicine commented: "We are very excited to be the first proton therapy center in the world to provide the CBCT 3D imaging solution. CBCT is a great tool for highly accurate patient positioning. It also enables the clinicians to assess the patient anatomical change over the treatment course regularly and to adapt the treatment plan whenever needed. The end results significantly benefit the patients, with enhanced precision and accuracy of the proton therapy delivery. We believe that this is another significant step in improving our ability to help patients achieve their goals of beating their cancer with as few side effects as possible."

Olivier Legrain, Chief Executive Officer of IBA commented: "We are very proud to be the first company in the world to provide the clinical proton therapy specific CBCT solution. The development of imaging capabilities is critical to the expansion of the use of proton therapy in new cancer indications and IBA has developed advanced radiation therapy solutions that improve the overall treatment experience for both clinicians and patients. CBCT is just one example of the latest technological advancements achieved by IBA that support our unrivalled position as the world's leader in the innovation and delivery of proton therapy."

Frederic Genin, Executive VP Product Management at IBA added: "IBA's significant experience and successful collaborations with key users make it possible to achieve this important milestone in the development of specific imaging solutions for proton therapy. The applications of image guidance and image monitoring are of paramount importance to benefit from the superior dose distribution of proton therapy. By adding Cone Beam CT as one of IBA's Image Guided Proton Therapy solutions, we are accelerating the development of Adaptive Proton Therapy."

** adaPTinsight is the first FDA cleared CBCT software solution in proton therapy. adaPTinsight is the brand name of the I2C software suite applicable to the IBA Proton Therapy solutions. (I2C: FDA 510(k) K132847).*

*** Proteus®PLUS is the brand name of a configuration of the Proteus® 235.*

**** Proteus®ONE is the brand name of a configuration of the Proteus® 235.*

-END-

Notes to editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and reduced side effects. Protons deposit the majority of their effective energy within a precisely controlled range within a tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide use IBA systems. This includes 17 proton therapy centers in operation and 12 centers under development. Over 25,000 patients have been treated with IBA equipment – more than all competitor installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Université catholique de Louvain - UCL

Université catholique de Louvain (UCL) is a comprehensive university founded in 1425 at the heart of Europe. UCL is one of the leading universities in Belgium with strong positions in the field of engineering and medicine. UCL has been the incubating institution for the IBA Company.

UCL's Image Group (Prof. B. Macq) of the ICTEAM research institute is a leading group in the field of medical imaging and video processing. The Image Group has developed the ImagX platform which handles in a very operational way recent results in the field of 3-D image processing, including 3-D co-registration, tomography and image reconstruction. This group is also involved in the simulation and validation processes of doses delivery.

UCL and IBA are jointly involved since more than 4 years in a public private partnership which aims at developing leading imaging technologies for image guided proton therapy.

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager Proton Therapy
+32 10 475 890
communication@iba-group.com